Synosia Licenses Rufinamide From Novartis In Anxiety, Bipolar Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
The sodium channel blocker could have advantages over selective serotonin reuptake inhibitors, CEO tells “The Pink Sheet” DAILY.